Metastatic Non Small Cell Lung Cancer Clinical Trials in Houston, Texas

7 recruitingHouston, Texas

Showing 17 of 7 trials

Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Metastatic Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center571 enrolled18 locationsNCT04410796
Recruiting
Phase 1

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaNon-small Cell Lung Cancer+4 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting
Phase 2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled91 locationsNCT04614103